Neumora expects to share additional updates on navacaprant development program at J.P. Morgan Healthcare Conference; podium presentation Tuesday, January 14 at 8:15am PT WATERTOWN, Mass., Jan. 02, ...
Neumora Therapeutics, Inc. (NMRA) is gearing up to report results from one of its phase 3 studies, which is using its drug Navacaprant for the treatment of patients with major depressive disorder (MDD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback